Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Cardiff Oncology (NASDAQ: CRDF) received a consensus rating of "Moderate Buy" from six brokerages, with four recommending buy, one hold, and one sell.
• In recent trading, Cardiff Oncology's stock is valued at $2.19 with a 52-week range of $1.90 to $5.64 and has a market capitalization of $145.70 million.
• Recently, Director Gary W. Pace purchased 15,000 shares at an average price of $2.45, increasing his holdings in the company.

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.6250.

A number of analysts have recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Cardiff Oncology in a research note on Saturday, September 27th. HC Wainwright dropped their price objective on Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. LADENBURG THALM/SH SH began coverage on Cardiff Oncology in a research report on Tuesday, July 8th. They set a "buy" rating and a $19.00 target price on the stock. Jefferies Financial Group began coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They set a "hold" rating and a $3.50 target price on the stock. Finally, William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th.

Insider Activity

In related news, Director Gary W. Pace purchased 15,000 shares of the firm's stock in a transaction dated Wednesday, July 30th. The stock was bought at an average price of $2.45 per share, for a total transaction of $36,750.00. Following the purchase, the director owned 1,345,676 shares in the company, valued at $3,296,906.20. The trade was a 1.13% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 7.70% of the company's stock.

Institutional Trading of Cardiff Oncology

A number of hedge funds have recently modified their holdings of CRDF. Engineers Gate Manager LP acquired a new stake in Cardiff Oncology during the 2nd quarter valued at $43,000. BNP Paribas Financial Markets raised its stake in shares of Cardiff Oncology by 335.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company's stock valued at $49,000 after purchasing an additional 11,889 shares during the period. Bank of America Corp DE raised its stake in shares of Cardiff Oncology by 189.3% in the 2nd quarter. Bank of America Corp DE now owns 93,393 shares of the company's stock valued at $294,000 after purchasing an additional 61,110 shares during the period. Glenview Trust co increased its position in shares of Cardiff Oncology by 79.9% in the second quarter. Glenview Trust co now owns 43,128 shares of the company's stock valued at $136,000 after acquiring an additional 19,150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company's stock worth $69,000 after purchasing an additional 4,232 shares during the period. Institutional investors own 16.29% of the company's stock.

Cardiff Oncology Price Performance

Shares of CRDF traded up $0.09 during midday trading on Friday, reaching $2.19. The stock had a trading volume of 1,357,173 shares, compared to its average volume of 807,664. Cardiff Oncology has a 52 week low of $1.90 and a 52 week high of $5.64. The firm's 50 day moving average price is $2.26 and its 200-day moving average price is $2.93. The company has a market capitalization of $145.70 million, a P/E ratio of -2.52 and a beta of 1.62.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%.The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.11 million. On average, equities analysts forecast that Cardiff Oncology will post -0.99 earnings per share for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.